Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Deep Vein Thrombosis (DVT) - Overview
Deep Vein Thrombosis (DVT) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Deep Vein Thrombosis (DVT) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
CarboMimetics
Chengdu Easton Biopharmaceuticals Co Ltd
Glycan Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
Protheragen Inc
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Deep Vein Thrombosis (DVT) - Drug Profiles
CM-20201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-3002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Redesca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NMMHC IIA for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zifa-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Deep Vein Thrombosis (DVT) - Dormant Projects
Deep Vein Thrombosis (DVT) - Discontinued Products
Deep Vein Thrombosis (DVT) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Cada
Sep 19, 2018: ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by CarboMimetics, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Glycan Therapeutics Inc, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Marizyme Inc, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Protheragen Inc, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020
Deep Vein Thrombosis (DVT) - Pipeline by Valeo Pharma Inc, H2 2020
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2020
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2020